Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel agents to modulate oestrogen action.

R C Dardes1, V C Jordan

  • 1Department of Gynaecology, Federal University of São Paulo, Brazil (UNIFESP).

British Medical Bulletin
|March 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.

British journal of cancer·2016
Same author

Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.

British journal of cancer·2016
Same author

Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

British journal of pharmacology·2014
Same author

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.

British journal of cancer·2014
Same author

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Clinical pharmacology and therapeutics·2013
Same author

Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

British journal of pharmacology·2013
Same journal

Augmentation in Achilles tendon repair: evidence versus enthusiasm.

British medical bulletin·2026
Same journal

Regional musculoskeletal pain in workers-is the traditional medical model increasing disability?

British medical bulletin·2026
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
See all related articles

Selective estrogen modulators (SERMs) offer a promising alternative to hormone replacement therapy for postmenopausal women, mitigating risks of osteoporosis and cardiovascular disease without adverse effects on breast and uterine health.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Women's Health

Background:

  • Menopause leads to decreased estrogen, increasing risks for osteoporosis and cardiovascular disease.
  • Hormone replacement therapy (HRT) has risks like increased cancer, limiting its use.
  • Selective estrogen modulators (SERMs) are a new drug class designed to mimic beneficial estrogen effects while avoiding harmful ones.

Purpose of the Study:

  • To review the development and application of SERMs in postmenopausal women.
  • To highlight SERMs' potential in preventing hormone-responsive breast cancer, osteoporosis, and cardiovascular disease.
  • To compare the efficacy and side effect profiles of specific SERMs like tamoxifen and raloxifene.

Main Methods:

  • Review of existing literature on SERMs, estrogen, and menopausal health.

Related Experiment Videos

  • Analysis of clinical trial data for tamoxifen and raloxifene.
  • Comparison of SERMs' tissue-specific effects (agonist vs. antagonist).

    • Main Results:

    • SERMs bind to estrogen receptors, providing tissue-specific benefits.
    • Tamoxifen shows benefits for bone density and lipids but can stimulate the endometrium.
    • Raloxifene prevents osteoporosis, lowers cholesterol, reduces breast cancer risk, and does not stimulate the endometrium.

    Conclusions:

    • SERMs represent a significant advancement in managing menopausal symptoms and age-related diseases.
    • SERMs offer a safer alternative to HRT for preventing osteoporosis, cardiovascular disease, and breast cancer in postmenopausal women.
    • Ongoing research and development of SERMs hold promise for improving women's health during aging.